Q-omics provides the consensus-scored MAFTRR profile across patient tissues and cancer cell-line models. MAFTRR expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MAFTRR is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, MAFTRR RNA expression shows 14,049 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, THCA, and TGCT as cancer lineages where MAFTRR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFTRR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFTRR survival associations across molecular data types. MAFTRR RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFTRR RNA expression–survival associations across cancer types. High MAFTRR expression shows unfavorable associations in LGG, but favorable associations in READ, UVM, COAD, UCS and LUSC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MAFTRR RNA expression.
This table summarizes MAFTRR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAFTRR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFTRR shows lower tumor expression in THCA, KICH, LUAD, BLCA, COAD and BRCA. The THCA box plot shows higher MAFTRR RNA expression in normal versus tumor tissue (log2 FC = −0.851, t-test p < 0.001).
This table shows molecular features associated with MAFTRR in patient tissues and cancer cell lines. In patient samples, MAFTRR shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
